Oral News and Research

RSS

Unigene enters Clinical Manufacturing Services Agreement with Cara Therapeutics

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company signed a Clinical Manufacturing Services Agreement with Cara Therapeutics, Inc.

19 May 2011

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat patients with acute infectious diseases and cardiovascular disorders, announced today that its lead defensin-mimetic antibiotic compound, PMX-30063, when administered topically as an oral rinse, has shown activity against oral mucositis in an animal study.

19 May 2011

Study: 10% of cancer patients fail to fill initial oral oncolytic prescriptions

Ten percent of cancer patients failed to fill their initial prescriptions for oral anti-cancer drugs, according to a new study published jointly today in the Journal of Oncology Practice and American Journal of Managed Care.

19 May 2011

Scientists identify key protein behind drug-resistant leukemia

Acute lymphoblastic leukemia, or ALL, is the most common form of childhood cancer. While most children treated for this disease survive, in a subgroup of patients the disease does not respond to treatment.

19 May 2011

Yoga offers unique benefits beyond fighting fatigue for women with breast cancer

For women with breast cancer undergoing radiation therapy, yoga offers unique benefits beyond fighting fatigue, according to new research from The University of Texas MD Anderson Cancer Center.

19 May 2011

State roundup: Med schools in Texas face budget crunch

Patients would have access to detailed histories of Illinois doctors — including whether the physician has been fired, convicted of a crime or made a medical malpractice payment in the past five years — under legislation headed to the governor's desk.

19 May 2011

Synergy expands GC-C agonist technology to lower cholesterol

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that it has successfully completed preclinical in vitro research demonstrating the inhibition of bile acid uptake by GC-C agonists and that it plans to commence animal studies shortly. Synergy believes this is the first time that GC-C agonists have been shown to potentially lower cholesterol.

18 May 2011

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Genentech, a member of the Roche Group, today announced that data showing new personalized approaches for people with skin and lung cancer, plus new data with Avastin in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology.

18 May 2011

Aeterna Zentaris first quarter revenues increase to $7.4 million

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported financial and operating results as at and for the first quarter ended March 31, 2011.

18 May 2011

Kool Smiles inaugurates new Takoma Park dental office

Kool Smiles, a leading dental health provider for children and adults, now has opened its doors to additional families in Maryland with a new office location in Takoma Park. Kool Smiles of Takoma Park officially opened on May 2 as the organization continues to expand access to quality dental care for families in underserved communities across the nation.

18 May 2011

EMAS publishes position statement on women's post-reproductive health problems in Maturitas journal

Elsevier announced the publication of an important position statement from the European Menopause and Andropause Society in the journal Maturitas on managing menopausal women with a personal or family history of venous thromboembolism.

18 May 2011

Unigene to present proprietary recombinant production, oral peptide drug delivery technology at TIDES Summit

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company will be presenting a poster and an oral presentation on its propriety recombinant production and oral peptide drug delivery technology during the upcoming 2011 TIDES: Oligonucleotide and Peptide Research, Technology and Product Development Summit being held at the Hynes Convention Center and Sheraton Boston Hotel in Boston, MA from May 22 - 25, 2011.

18 May 2011

African-American children have poor lung function at their initial visit to asthma specialist

African-American children are more likely to report previous emergency room visits, hospitalizations and need for intensive care unit management for asthma than Caucasian children on their first visit to an asthma specialist, according to a study conducted by researchers at Johns Hopkins University.

18 May 2011

Gut bacteria influences brain chemistry and behaviour: Research

For the first time, researchers at McMaster University have conclusive evidence that bacteria residing in the gut influence brain chemistry and behaviour.

18 May 2011

Positive results from Astellas Pharma's mirabegron phase III trial in overactive bladder

Astellas Pharma US, Inc., U.S. subsidiary of Astellas Pharma Inc., today announced the results of a pivotal phase III clinical trial for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), which show mirabegron significantly improves key OAB symptoms – urinary incontinence and frequency of micturition compared with placebo.

18 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, in Canada at St. Joseph's Healthcare - Hamilton, Ontario.

18 May 2011

Anavex comments on new Alzheimer’s disease diagnostic guidelines

Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today commented on new diagnostic criteria and guidelines for Alzheimer’s disease published recently by the National Institute on Aging (NIA) and the Alzheimer’s Association, which have been updated for the first time in more than 25 years. The new guidelines discuss the importance of new technologies, including brain imaging and biomarker analysis, in research and clinical diagnosis. They describe Alzheimer’s disease at a preclinical stage, Mild Cognitive Impairment (MCI) due to Alzheimer’s disease, and dementia due to Alzheimer’s pathology.

18 May 2011

Pernix first quarter net revenues increase 14% to $10.1 million

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company primarily focused on the pediatric market, today announced financial results for the first quarter of 2011.

17 May 2011

Daiichi Sankyo, Regency Therapeutics launch SPRIX Nasal Spray for severe pain

Regency Therapeutics, a newly established division of Luitpold Pharmaceuticals, Inc., and its co-promotion partner Daiichi Sankyo, Inc., announced today that they have launched SPRIX® (ketorolac tromethamine) Nasal Spray and that it is now commercially available.

17 May 2011

Pfizer seeks U.S. FDA, Japanese MHLW approval for crizotinib NDA to treat ALK-positive advanced NSCLC

Pfizer Inc. announced today that its New Drug Application for crizotinib, an oral first-in-class anaplastic lymphoma kinase inhibitor, has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration and has been filed with the Japanese Ministry of Health, Labour and Welfare.

17 May 2011

Oral News and Research

Unigene enters Clinical Manufacturing Services Agreement with Cara Therapeutics

PolyMedix's PMX-30063 compound mitigates ulcerative mucositis in pre-clinical studies

Study: 10% of cancer patients fail to fill initial oral oncolytic prescriptions

Scientists identify key protein behind drug-resistant leukemia

Yoga offers unique benefits beyond fighting fatigue for women with breast cancer

State roundup: Med schools in Texas face budget crunch

Synergy expands GC-C agonist technology to lower cholesterol

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Aeterna Zentaris first quarter revenues increase to $7.4 million

Kool Smiles inaugurates new Takoma Park dental office

EMAS publishes position statement on women's post-reproductive health problems in Maturitas journal

Unigene to present proprietary recombinant production, oral peptide drug delivery technology at TIDES Summit

African-American children have poor lung function at their initial visit to asthma specialist

Gut bacteria influences brain chemistry and behaviour: Research

Positive results from Astellas Pharma's mirabegron phase III trial in overactive bladder

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

Anavex comments on new Alzheimer’s disease diagnostic guidelines

Pernix first quarter net revenues increase 14% to $10.1 million

Daiichi Sankyo, Regency Therapeutics launch SPRIX Nasal Spray for severe pain

Pfizer seeks U.S. FDA, Japanese MHLW approval for crizotinib NDA to treat ALK-positive advanced NSCLC

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News